- Home
- KYTX vs RAPT Comparison
KYTX vs RAPT Comparison
Compare KYTX & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYTX
- RAPT
- Stock Information
- Founded
- KYTX 2018
- RAPT 2015
- Country
- KYTX United States
- RAPT United States
- Employees
- KYTX N/A
- RAPT N/A
- Industry
- KYTX
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- KYTX
- RAPT Health Care
- Exchange
- KYTX NYSE
- RAPT Nasdaq
- Market Cap
- KYTX 125.2M
- RAPT 117.5M
- IPO Year
- KYTX 2024
- RAPT 2019
- Fundamental
- Price
- KYTX $1.86
- RAPT $0.79
- Analyst Decision
- KYTX Buy
- RAPT Hold
- Analyst Count
- KYTX 5
- RAPT 7
- Target Price
- KYTX $18.80
- RAPT $5.00
- AVG Volume (30 Days)
- KYTX 298.8K
- RAPT 1.1M
- Earning Date
- KYTX 05-13-2025
- RAPT 05-08-2025
- Dividend Yield
- KYTX N/A
- RAPT N/A
- EPS Growth
- KYTX N/A
- RAPT N/A
- EPS
- KYTX N/A
- RAPT N/A
- Revenue
- KYTX N/A
- RAPT N/A
- Revenue This Year
- KYTX N/A
- RAPT N/A
- Revenue Next Year
- KYTX N/A
- RAPT N/A
- P/E Ratio
- KYTX N/A
- RAPT N/A
- Revenue Growth
- KYTX N/A
- RAPT N/A
- 52 Week Low
- KYTX $1.79
- RAPT $0.79
- 52 Week High
- KYTX $22.44
- RAPT $8.58
- Technical
- Relative Strength Index (RSI)
- KYTX 39.01
- RAPT 31.31
- Support Level
- KYTX $1.81
- RAPT $0.81
- Resistance Level
- KYTX $2.27
- RAPT $0.98
- Average True Range (ATR)
- KYTX 0.21
- RAPT 0.10
- MACD
- KYTX 0.02
- RAPT -0.03
- Stochastic Oscillator
- KYTX 16.33
- RAPT 7.72
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.